Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1

• DOI: 10.1038/37995
• Publication Date: 2002-07-26T08:37:10Z
• Authors: Franz-Xaver Gomis...; Klaus Maskos; Michael Betz; Andreas Bergner; Robert Huber; Ko Suzuki; Naoki Yoshida; Hideaki Nagase; Keith Brew; Gleb P. Bourenkov; Hans Bartunik; Wolfram Bode
• Keywords: Models, Molecular; 0303 health sciences; Binding Sites; Glycosylation; Protein Conformation; Tissue Inhibitor of Metalloproteinases; info:eu-repo/classification/ddc/070; Matrix Metalloproteinase Inhibitors; Crystallography, X-Ray; 03 medical and health sciences; Drug Design; Humans; Matrix Metalloproteinase 3; Protease Inhibitors; Glycoproteins

Matrix metalloproteinases (MMPs) are zinc endopeptidases that are required for the degradation of extracellular matrix components during normal embryo development, morphogenesis and tissue remodelling. Their proteolytic activities are precisely regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). Disruption of this balance results in diseases such as arthritis, atherosclerosis, tumour growth and metastasis. Here we report the crystal structure of an MMP-TIMP complex formed between the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1. TIMP-1, a 184-residue protein, has the shape of an elongated, contiguous wedge. With its long edge, consisting of five different chain regions, it occupies the entire length of the active-site cleft of MMP-3. The central disulphide-linked segments Cys 1-Thr 2-Cys 3-Val 4 and Ser 68-Val 69 bind to either side of the catalytic zinc. Cys 1 bidentally coordinates this zinc, and the Thr-2 side chain extends into the large specificity pocket of MMP-3. This unusual architecture of the interface between MMP-3 and TIMP-1 suggests new possibilities for designing TIMP variants and synthetic MMP inhibitors with potential therapeutic applications.